secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kalaris Therapeutics, Inc. (KLRS)
CIK:        0001754068
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001193125-22-276390
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AlloVir reports Q3 net loss $42.1M; cash $264.1M, advancing Phase 3 posoleucel trials
--------------------------------------------------------------------------------

- Net loss of $42.1M ($0.50/sh) in Q3 2022 vs $45.5M ($0.72) in Q3 2021.
- Cash & securities $264.1M; raised $126.4M net from registered direct offering July 2022.
- R&D expenses $30.0M, G&A $12.9M; FY2022 opex guidance $130M-$145M excl. stock comp.
- Phase 3 posoleucel trials ongoing; final Phase 2 multi-virus prevention data by year-end.
- Topline Phase 2 BK viremia data in kidney transplant patients expected Q1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1754068/000119312522276390/0001193125-22-276390-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1754068/000119312522276390/d408523d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-276390

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer